These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications. Celik T; Iyisoy A; Yuksel UC; Kardesoglu E Int J Cardiol; 2008 Aug; 128(1):97-9; authr reply 100-2. PubMed ID: 18501448 [TBL] [Abstract][Full Text] [Related]
24. [Alternatives to conventional diuretic therapy in heart failure]. Morales-Rull JL; Trullàs JC; Formiga F Med Clin (Barc); 2014 Mar; 142 Suppl 1():42-8. PubMed ID: 24930083 [TBL] [Abstract][Full Text] [Related]
25. [Organ damage and cardiorenal syndrome in acute heart failure]. Casado Cerrada J; Pérez Calvo JI Med Clin (Barc); 2014 Mar; 142 Suppl 1():26-31. PubMed ID: 24930080 [TBL] [Abstract][Full Text] [Related]
26. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions. Díez J Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581 [TBL] [Abstract][Full Text] [Related]
27. Relaxin: a novel agent for the treatment of acute heart failure. Wilson SS; Ayaz SI; Levy PD Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289 [TBL] [Abstract][Full Text] [Related]
28. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697 [TBL] [Abstract][Full Text] [Related]
29. [Vasoactive and inotropic drugs in acute heart failure]. Ruiz-Laiglesia FJ; Camafort-Babkowski M Med Clin (Barc); 2014 Mar; 142 Suppl 1():49-54. PubMed ID: 24930084 [TBL] [Abstract][Full Text] [Related]
34. Emerging role of serelaxin in the therapeutic armamentarium for heart failure. Varr BC; Maurer MS Curr Atheroscler Rep; 2014 Oct; 16(10):447. PubMed ID: 25108571 [TBL] [Abstract][Full Text] [Related]
35. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Teerlink JR Am Heart J; 2003 Feb; 145(2 Suppl):S26-33. PubMed ID: 12594449 [No Abstract] [Full Text] [Related]
36. Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond. Cotter G; Milo O; Davison BA Curr Heart Fail Rep; 2014 Mar; 11(1):19-30. PubMed ID: 24363020 [TBL] [Abstract][Full Text] [Related]
37. The development of new medical treatments for acute decompensated heart failure. Teerlink JR Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887 [TBL] [Abstract][Full Text] [Related]
38. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144 [TBL] [Abstract][Full Text] [Related]
39. Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure? Dschietzig TB Am J Cardiovasc Drugs; 2014 Oct; 14(5):343-55. PubMed ID: 24934696 [TBL] [Abstract][Full Text] [Related]
40. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]